10-Q: FMC Q3 2025: India Divestment Hits Revenue, Dividend Cut

FMC Corporation reports a significant net loss in Q3 2025 due to a $510 million charge from its India business divestment and announces a dividend reduction to prioritize debt.

Summary

• Net loss attributable to FMC stockholders was $(569.3) million for Q3 2025, a substantial decrease from $65.0 million net income in Q3 2024.
• Revenue for Q3 2025 decreased by 49% to $542.2 million, primarily driven by $419 million in revenue charges from one-time commercial actions related to the India business divestment.
• The company recorded $510 million in total charges and write-downs in Q3 2025 for the India business divestment, including $282.2 million in commercial actions and a $226.8 million asset impairment.
• Adjusted EBITDA (Non-GAAP), excluding India business operating results for Q3 2025, increased 17% to $236.1 million from $201.4 million in Q3 2024.
• Adjusted after-tax earnings from continuing operations (Non-GAAP), excluding India business operating results for Q3 2025, increased 29% to $112.4 million from $87.2 million in Q3 2024.
• The quarterly dividend will be reduced to $0.08 per share beginning with the December 2025 declaration to prioritize debt reduction.
• Share repurchases under the publicly announced program are suspended until December 31, 2027, due to an amendment to the company's credit agreement.
• Project Focus restructuring charges were $49.9 million in Q3 2025, with total estimated pre-tax charges for the program increased to a range of $425 million to $475 million.
• The company was in compliance with all debt covenants at September 30, 2025, with actual leverage of 4.94 (below max 5.25) and interest coverage of 3.93 (above min 3.00).
• The 2025 full-year outlook for revenue (excluding India) is expected to be $3.92 billion to $4.02 billion (down 7% at midpoint vs. 2024), Adjusted EBITDA $830 million to $870 million (down 6% at midpoint vs. 2024), and Adjusted EPS $2.92 to $3.14 (down 13% at midpoint vs. 2024).
• Free cash flow for 2025 is expected to be in the range of negative $200 million to zero.

Sentiment

Score: 3

Explanation: While strategic actions are underway to improve long-term competitiveness and some adjusted metrics show improvement (excluding India), the substantial GAAP net loss, significant revenue decline, dividend cut, and suspension of share repurchases indicate a challenging period and a negative short-term outlook. The negative free cash flow outlook further reinforces this.

Positives

• Adjusted EBITDA (Non-GAAP), excluding India business operating results for Q3 2025, increased 17% to $236.1 million compared to $201.4 million in Q3 2024.
• Adjusted after-tax earnings from continuing operations (Non-GAAP), excluding India business operating results for Q3 2025, increased 29% to $112.4 million compared to $87.2 million in Q3 2024.
• Gross margin as a percent of revenue (excluding the impact of one-time commercial actions in India) increased to approximately 43% in Q3 2025 from 36% in Q3 2024, driven by continued cost improvement.
• North America revenue increased approximately 4% year-over-year in Q3 2025, primarily due to higher volume in the growth portfolio and branded Rynazypyr active.
• Europe, Middle East & Africa (EMEA) revenue increased approximately 11% (7% organically) in Q3 2025, driven by higher volumes in the growth portfolio and the recent launch of Isoflex active in Great Britain.
• The company was in compliance with all debt covenants at September 30, 2025, with an actual leverage ratio of 4.94 (below the maximum of 5.25) and an actual interest coverage ratio of 3.93 (above the minimum of 3.00).
• The Project Focus restructuring program is expected to achieve targeted annual run-rate savings of more than $225 million by the end of 2025.

Negatives

• Reported a net loss attributable to FMC stockholders of $(569.3) million in Q3 2025, a significant decline from net income of $65.0 million in Q3 2024.
• Revenue decreased 49% to $542.2 million in Q3 2025, primarily due to $419 million in revenue charges from one-time commercial actions to prepare the India business for sale.
• Gross margin decreased by $257.5 million, or approximately 67%, in Q3 2025, largely due to the India commercial actions.
• Recorded $510 million in total charges and write-downs in Q3 2025 related to the India business divestment, including a $226.8 million asset impairment charge.
• The quarterly dividend was reduced to $0.08 per share starting December 2025, indicating a need to prioritize debt reduction.
• Share repurchases under the publicly announced program are suspended until December 31, 2027, as part of an amendment to the credit agreement.
• Latin America revenue decreased approximately 8% (9% organically) in Q3 2025 due to lower pricing, generic pressure, and customer credit constraints in Brazil and Argentina.
• Asia revenue decreased approximately 271% in Q3 2025, primarily due to the India commercial actions; excluding India, Asia revenue was down 47% (46% organically) due to lower volumes and pricing pressure.
• The 2025 full-year outlook projects decreases in revenue (excluding India) by 7%, Adjusted EBITDA by 6%, and Adjusted EPS by 13% at the midpoint compared to 2024.
• The free cash flow outlook for 2025 is negative $200 million to zero, indicating a cash outflow or breakeven scenario.
• Recorded a valuation allowance of approximately $47 million against historical deferred tax assets due to the enacted One Big Beautiful Bill Act.
• Incurred $7.7 million in currency-related charges in Q3 2025 due to devaluation actions by the Argentine Government.
• Recorded a charge of $11.9 million due to changes in the estimate for Furadan disposal costs at the Middleport site.

Risks

• Ongoing commercial challenges in India led to the decision to divest the commercial business, indicating market difficulties.
• Increased competitive pressure and generic competition in the crop protection market, particularly in Latin America and Asia, are driving lower pricing.
• Low liquidity in Brazil and Argentina is causing customer credit constraints, inhibiting growth in Latin America.
• Uncertainties regarding the status of environmental laws, regulations, enforcement policies, and the impact of potentially responsible parties could lead to actual future environmental losses exceeding the accrued amounts (estimated reasonably possible environmental loss contingencies, net of expected recoveries, exceed amounts accrued by approximately $290 million at September 30, 2025).
• Future effective tax rates may be materially impacted by changes in the composition of earnings from foreign and domestic tax jurisdictions.
• Significant volatility in interim tax provisions can occur due to changes in tax rates or laws, finalization of tax audits, and discrete items.
• The Pillar Two Model Rules for global minimum tax and the January 2025 OECD guidance limiting the economic benefit of Swiss credits may result in the company paying more top-up tax in the future.
• Exposure to market risks related to fluctuations in commodity prices, interest rates, and foreign currency exchange rates.
• Derivative litigation filed by purported shareholders alleges breach of fiduciary duties and other misconduct by certain current and former officers and directors, creating legal and reputational risk.
• Future cash dividends are subject to a variety of factors and Board determination, implying potential for further changes.
• Additional asset write-off charges and other exit and disposal costs may be incurred if further activities are implemented under the Project Focus restructuring program.

Future Outlook

The company expects 2025 revenue (excluding India) to be in the range of $3.92 billion to $4.02 billion, representing a 7% decrease at the midpoint versus 2024. Volume is anticipated to improve due to new products and an expanded route to market in Brazil, but pricing is expected to decline in the mid-to-high single digits due to increased competitive pressure and contract adjustments. Foreign currency impacts are projected to be flat to a low-single digit headwind. Adjusted EBITDA for 2025 is forecast to be $830 million to $870 million, down 6% at the midpoint, and adjusted earnings are expected to be $2.92 to $3.14 per diluted share, down 13% at the midpoint. Free cash flow for 2025 is projected to be between negative $200 million and zero. The sale process for the India commercial business is expected to conclude within the next twelve months. The company plans to amend its revolving credit facility's financial covenants in Q4 2025 and has reduced its quarterly dividend to $0.08 per share starting December 2025.

Management Comments

• We continue to evaluate our business to ensure alignment with strategic priorities and have concluded that a redesign of our manufacturing footprint is both necessary and timely.
• We intend to exit high-cost active ingredient and formulation sources and transition production to lower-cost sources.
• We are also implementing cost reduction initiatives in Asia to adjust for the reduced size of the regions business following the intended sale of our India commercial business.
• These actions are designed to establish a cost-competitive structure that enables FMC to better compete with generics while capturing the full value of its innovative technology portfolio.
• As part of a broader response to the challenges the company is facing and to further prioritize debt reduction, the Board of Directors has made the decision to reduce the quarterly dividend to $0.08 per share beginning with the dividend declaration in December 2025.
• Future cash dividends, as always, will depend on a variety of factors, including earnings, capital requirements, financial condition, general economic conditions and other factors considered relevant by us and is subject to final determination by our Board of Directors.
• The company has a long history of returning cash to shareholders and will continue to evaluate its capital allocation on an ongoing basis.

Industry Context

FMC Corporation operates in the global agricultural sciences sector, focusing on crop protection chemicals (insecticides, herbicides, fungicides) and plant health products. The company's restructuring plan, 'Project Focus,' was initiated in response to a significant drop in demand across the crop protection market in 2023. The strategic actions, including the India divestment and manufacturing footprint redesign, aim to establish a cost-competitive structure to better compete with generics. The filing highlights ongoing pricing pressure due to increased competitive dynamics and generic competition, particularly in Latin America and Asia, which are key markets for the company.

Comparison to Industry Standards

• The filing notes increased competitive pressure and generic competition in the market, particularly in Latin America and Asia, which is impacting pricing.
• The company's strategic actions, such as exiting high-cost active ingredient sources, are aimed at establishing a cost-competitive structure to better compete with generics.
• No specific comparable companies, projects, or results are detailed in the filing for a direct assessment against global benchmarks.

Corporate Governance

Legal Proceedings

• Derivative actions filed by purported FMC shareholders on January 23, 2025, and June 2, 2025, in the Eastern District of Pennsylvania, alleging breach of fiduciary duties and other misconduct by certain current and former officers and directors, based on alleged misstatements and omissions in the Consolidated Securities Class Action. These cases are consolidated and stayed.
• Derivative actions filed by purported FMC shareholders on May 29, 2025, and June 16, 2025, in the Eastern District of Pennsylvania, alleging breach of fiduciary duties and other misconduct by certain current and former officers and directors, based on alleged misstatements and omissions in the Mohammed and Macomb County Actions. These cases are consolidated and expected to be stayed.
• A derivative action filed on July 9, 2025, in the Eastern District of Pennsylvania (Beard v. Douglas, et al.), alleging breach of fiduciary duties and other misconduct by certain current and former officers and directors, based on alleged misstatements and omissions in the Consolidated Securities Class Action and the Mohammed and Macomb County Actions. This matter is at a very preliminary stage.
• A derivative action filed on July 16, 2025, in the United States District Court for the District of Delaware (Fallarino v. Douglas, et al.), alleging breach of fiduciary duties and other misconduct by certain current and former officers and directors, based on alleged misstatements and omissions in the Mohammed and Macomb County Actions. This matter is at a very preliminary stage.
• Recorded a $34.5 million reduction in the required legal reserve in discontinued operations during Q2 2025 due to a decrease in outstanding cases.

Stakeholder Impact

• Shareholders: Experience a significant net loss, a substantial dividend reduction to $0.08 per share, and a suspension of share repurchases, indicating reduced direct returns and a challenging financial period. Derivative litigation also introduces uncertainty.
• Employees: The Project Focus restructuring initiative includes severance and employee separation costs, suggesting potential workforce adjustments.
• Customers: Faced with pricing changes and product returns in India due to commercial actions related to the divestment. Customers in Brazil and Argentina are experiencing credit constraints due to low liquidity.
• Creditors: The company issued $750 million in Subordinated Notes and redeemed $500 million in senior notes. Debt covenants were amended to provide financial flexibility, and the company remains in compliance, which is positive for creditors.
• Suppliers: Offered a voluntary Supply Chain Finance (SCF) program, which can impact their payment terms and cash flow management.

Next Steps

• The sale process for the India commercial business is underway and expected to conclude within the next twelve months.
• The company plans to continue actively participating in the India market through a supply agreement with the eventual buyer for its patented and data-protected portfolio.
• The company will continue its active ingredients manufacturing operations in India.
• Anticipate executing an amendment to the revolving credit facility's financial covenants in Q4 2025 to provide additional financial flexibility.
• The Project Focus restructuring plan is expected to be complete by the end of 2025, aiming for more than $225 million in annual run-rate savings.
• The quarterly dividend will be reduced to $0.08 per share beginning with the December 2025 declaration.
• The company will continue to evaluate its capital allocation on an ongoing basis.
• The company is continuing to evaluate the income tax implications of the One Big Beautiful Bill Act.
• The company will continue to evaluate the impact of the Pillar Two Framework as legislative changes are enacted and additional guidance becomes available.

Key Dates

Recommendation

The substantial GAAP net loss of $(569.3) million, primarily driven by a $510 million charge from the India business divestment, coupled with a 49% revenue decline, signals severe operational challenges. The decision to cut the quarterly dividend to $0.08 per share and suspend share repurchases until 2027 indicates a prioritization of debt reduction over shareholder returns, reflecting a strained financial position. While adjusted EBITDA and earnings show some improvement when excluding the India impact, the overall picture, including a negative free cash flow outlook for 2025, suggests ongoing headwinds and a need for significant restructuring. The derivative litigation adds further uncertainty. For a seasoned investor, these factors point to a period of significant instability and a likely negative impact on stock performance, warranting a 'sell' recommendation.

Keywords

FMC Corporation, 10-Q, Quarterly Report, Crop Protection, Agricultural Sciences, India Divestment, Asset Impairment, Dividend Reduction, Adjusted EBITDA, Net Loss, Project Focus, Restructuring, Debt Covenants, Free Cash Flow, Environmental Liabilities, Legal Proceedings, Foreign Currency Risk, Pricing Pressure, Generic Competition, Share Repurchase Suspension, Subordinated Notes